Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pharmacokinetic trial of 30‑minute infusion of PM02734 in non‑small cell lung cancer
2008-004908-31Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Oct 2008
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elisidepsin in non-small cell lung cancer (NSCLC), sponsored by PharmaMar. Primary endpoints: Antitumor activity of PM02734, Safety profile of PM02734 regimen and 1 more. Started Oct 2008; status: completed.
02
Drugs
elisidepsin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-004908-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004908-31.